Apellis Pharmaceuticals auf LinkedIn: Apellis Announces 24-Month Results Showing Increased Effects Over Time… | 11 Kommentare
Apellis unveils 18-month results from phase 3 OAKS and DERBY studies
Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA) | BioSpace
Apellis Submits NDA to the FDA for Pegcetacoplan | OBN
Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer - Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Stock: Trying To Develop A Blockbuster Franchise (NASDAQ:APLS) | Seeking Alpha
Apellis Pharmaceuticals auf LinkedIn: Apellis Announces 24-Month Results Showing Increased Effects Over Time… | 11 Kommentare
Recruiting patients with geographic atrophy secondary to AMD for phase 3 trials | Apellis APL-2 Opthalmic Trial
Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) – Epidarex
%20copy_1651527917.jpg "Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA)")
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA)
%20copy_1661347616.jpg "Apellis Announces 24-Month Results in Phase 3 Studies Examining Pegcetacoplan in Geographic Atrophy (GA)")
Apellis Announces 24-Month Results in Phase 3 Studies Examining Pegcetacoplan in Geographic Atrophy (GA)
Apellis finds that one of its twins is evil | Evaluate
Efficacy of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials
Apellis Pharmaceuticals Stock: Trying To Develop A Blockbuster Franchise (NASDAQ:APLS) | Seeking Alpha
Apellis Pharma (@ApellisPharma) / Twitter
Markets remain unimpressed by Apellis as PDUFA date draws near
Apellis Building on Its Platform with APL-2 for Geographic Atrophy | Ophthalmology Innovation Source
Apellis receives mixed results in two Phase 3 studies
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
Hope in sight with Apellis' pegcetacoplan OAKS/DERBY results for GA -
Recruiting patients with geographic atrophy secondary to AMD for phase 3 trials | Apellis APL-2 Opthalmic Trial
Apellis finds that one of its twins is evil | Evaluate
